BACE1 and Alzheimer disease: Taken together, the findings of this investigation indicate that EMPA markedly enhanced behavioral impairments during the MWM and NOR tests and also affected signaling pathways such as upregulation of AMPK/mTOR and HO-1, reducing AD hallmarks (Aβ and BACE1), oxidative stress, and neuroinflammation consequences.